Cargando…
Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report
Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully exp...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685185/ https://www.ncbi.nlm.nih.gov/pubmed/38034719 http://dx.doi.org/10.1016/j.heliyon.2023.e21582 |
_version_ | 1785151573553315840 |
---|---|
author | Chen, Ruiqi Zhao, Lilan Zhang, Juan Guo, Lingwen Chen, Zhizhong Pan, Xiaojie Chen, Wenshu |
author_facet | Chen, Ruiqi Zhao, Lilan Zhang, Juan Guo, Lingwen Chen, Zhizhong Pan, Xiaojie Chen, Wenshu |
author_sort | Chen, Ruiqi |
collection | PubMed |
description | Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully explored. This case study describes the clinical progression of a patient initially diagnosed with unresectable stage III (cT1bN2M0) lung adenocarcinoma, who was later discovered to harbor an ALK mutation through next-generation sequencing. The patient underwent surgery to achieve a radical resection of the right upper lung lesion after neoadjuvant therapy with lorlatinib and a pathological complete response (pCR) was confirmed by pathological analysis. To our knowledge, it has never been reported that neoadjuvant therapy with lorlatinib resulted in pCR for an ALK-positive patient with stage III NSCLC who was initially unresectable. Therefore, our findings indicate that utilizing ALK-TKIs as neoadjuvant therapy could be considered a viable choice for ALK-positive NSCLC patients. |
format | Online Article Text |
id | pubmed-10685185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106851852023-11-30 Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report Chen, Ruiqi Zhao, Lilan Zhang, Juan Guo, Lingwen Chen, Zhizhong Pan, Xiaojie Chen, Wenshu Heliyon Case Report Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have demonstrated substantial effectiveness in individuals with advanced ALK-positive non-small cell lung cancer (NSCLC). However, the controversy over using ALK-TKIs for neoadjuvant therapy in ALK-positive NSCLC has not been fully explored. This case study describes the clinical progression of a patient initially diagnosed with unresectable stage III (cT1bN2M0) lung adenocarcinoma, who was later discovered to harbor an ALK mutation through next-generation sequencing. The patient underwent surgery to achieve a radical resection of the right upper lung lesion after neoadjuvant therapy with lorlatinib and a pathological complete response (pCR) was confirmed by pathological analysis. To our knowledge, it has never been reported that neoadjuvant therapy with lorlatinib resulted in pCR for an ALK-positive patient with stage III NSCLC who was initially unresectable. Therefore, our findings indicate that utilizing ALK-TKIs as neoadjuvant therapy could be considered a viable choice for ALK-positive NSCLC patients. Elsevier 2023-11-02 /pmc/articles/PMC10685185/ /pubmed/38034719 http://dx.doi.org/10.1016/j.heliyon.2023.e21582 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Chen, Ruiqi Zhao, Lilan Zhang, Juan Guo, Lingwen Chen, Zhizhong Pan, Xiaojie Chen, Wenshu Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title | Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title_full | Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title_fullStr | Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title_full_unstemmed | Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title_short | Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report |
title_sort | pathological complete response to neoadjuvant lorlatinib in a patient with unresectable alk-positive locally advanced non-small cell lung cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685185/ https://www.ncbi.nlm.nih.gov/pubmed/38034719 http://dx.doi.org/10.1016/j.heliyon.2023.e21582 |
work_keys_str_mv | AT chenruiqi pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT zhaolilan pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT zhangjuan pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT guolingwen pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT chenzhizhong pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT panxiaojie pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport AT chenwenshu pathologicalcompleteresponsetoneoadjuvantlorlatinibinapatientwithunresectablealkpositivelocallyadvancednonsmallcelllungcanceracasereport |